Pfizer Inc. (NYSE:PFE) Stake Boosted by Aberdeen Group plc

Aberdeen Group plc increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 32.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,934,150 shares of the biopharmaceutical company's stock after purchasing an additional 1,196,663 shares during the quarter. Aberdeen Group plc owned approximately 0.09% of Pfizer worth $123,280,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Horizon Investments LLC increased its stake in Pfizer by 4.4% in the 1st quarter. Horizon Investments LLC now owns 86,200 shares of the biopharmaceutical company's stock worth $2,144,000 after purchasing an additional 3,598 shares in the last quarter. Providence Capital Advisors LLC increased its stake in Pfizer by 1.3% in the 1st quarter. Providence Capital Advisors LLC now owns 115,793 shares of the biopharmaceutical company's stock worth $2,934,000 after purchasing an additional 1,435 shares in the last quarter. Fox Run Management L.L.C. purchased a new position in Pfizer in the 1st quarter worth about $3,003,000. Inspire Trust Co. N.A. boosted its position in Pfizer by 4.3% during the 1st quarter. Inspire Trust Co. N.A. now owns 105,000 shares of the biopharmaceutical company's stock worth $2,661,000 after acquiring an additional 4,292 shares during the period. Finally, Kovitz Investment Group Partners LLC boosted its position in Pfizer by 129.2% during the 1st quarter. Kovitz Investment Group Partners LLC now owns 394,212 shares of the biopharmaceutical company's stock worth $9,989,000 after acquiring an additional 222,218 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.12 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business's 50 day moving average is $24.56 and its two-hundred day moving average is $24.46. The company has a market cap of $142.79 billion, a P/E ratio of 13.36, a P/E/G ratio of 0.90 and a beta of 0.52. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.60 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 91.49%.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Cantor Fitzgerald initiated coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Finally, UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer currently has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.